Sphere Fluidics’ Cyto-Mine® platform, harnesses proprietary picodroplet-based technology to capture and screen antibodies directly from whole B cell repertoires, preserving cell viabilities and dramatically improving efficiencies.

In this eBook, we describe a robust and rapid single B cell screening method to identify antibodies of desired antigenic specificity without the laborious need for traditional hybridoma screening. Sphere Fluidics’ Cyto-Mine® platform, harnesses proprietary picodroplet-based technology to capture and screen antibodies directly from whole B cell repertoires, preserving cell viabilities and dramatically improving efficiencies. Using this method, researchers can identify antibody-secreting cells and isolate rare cells secreting antigen-specific antibodies in just two days, significantly accelerating the time-to-market for therapeutics. Download to continue reading…